Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation

International Journal of Hematology

Volumn 90, Issue 2, 2009, Pages 127-136

  Ohta, Hideaki ^a   Fukushima, Norihide ^b   Ozono, Keiichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cardiac transplantation; EBV; Immunosuppression; Pediatric; Post transplant lymphoproliferative disorder

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLUORODEOXYGLUCOSE; GANCICLOVIR; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR; VINCRISTINE;

AIRWAY; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CHILD CARE; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; EPSTEIN BARR VIRUS; GASTROINTESTINAL TRACT; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOLOGY; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LUNG; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; POSTOPERATIVE COMPLICATION; REVIEW; RISK FACTOR; SERODIAGNOSIS; SYSTEMIC DISEASE; VIRUS INFECTION; VIRUS LOAD;

CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 70350569195     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0399-x     Document Type: Review

References (99)

1. MM Boucek DA Waltz LB Edwards DO Taylor BM Keck EP Trulock, et al. 2006 Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report-2006 J Heart Lung Transplant 25 893 903 16890109 10.1016/j.healun.2006.05.014 (Pubitemid 44143014)
2. JK Preiksaitis 2004 New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients Clin Infect Dis 39 1016 1023 15472855 10.1086/424447 (Pubitemid 39313460)
3. R Shaknovich K Basso G Bhagat M Mansukhani G Hatzivassiliou VV Murty, et al. 2006 Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling Haematologica 91 1313 1320 17018379 1:CAS:528:DC%2BD28XhtF2gsr7E
4. E Klein LL Kis G Klein 2007 Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions Oncogene 26 1297 1305 17322915 10.1038/sj.onc.1210240 1:CAS:528:DC%2BD2sXitVKhsLw%3D (Pubitemid 46328467)
5. B Zawilinska A Kosinska M Lenart J Kopec B Piatkowska-Jakubas A Skotnicki, et al. 2008 Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load Acta Biochim Pol 55 693 699 19015775 1:CAS:528:DC%2BD1MXht1Skt7w%3D
6. S Gottschalk CM Rooney HE Heslop 2005 Post-transplant lymphoproliferative disorders Annu Rev Med 56 29 44 15660500 10.1146/annurev.med.56.082103.104727 1:CAS:528:DC%2BD2MXisVSrsLs%3D (Pubitemid 40299772)
7. R Kuppers 2003 B cells under influence: transformation of B cells by Epstein-Barr virus Nat Rev Immunol 3 801 812 14523386 10.1038/nri1201
8. HH Niller D Salamon K Ilg A Koroknai F Banati G Bauml, et al. 2003 The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis Med Sci Monit 9 HY1 9 12552250 1:CAS:528:DC%2BD3sXhs1ymtrY%3D
9. SA Webber DC Naftel FJ Fricker P Olesnevich ED Blume L Addonizio, et al. 2006 Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study Lancet 367 233 239 16427492 10.1016/S0140-6736(06) 67933-6 (Pubitemid 43107668)
10. S Schubert H Abdul-Khaliq HB Lehmkuhl M Yegitbasi P Reinke C Kebelmann-Betzig, et al. 2009 Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients Pediatr Transplant 13 54 62 18518912 10.1111/j.1399-3046.2008.00969.x 1:STN:280:DC%2BD1M%2Fns1KktQ%3D%3D
11. S Ohga A Nomura H Takada T Hara 2002 Immunological aspects of Epstein-Barr virus infection Crit Rev Oncol Hematol 44 203 215 12467961 10.1016/S1040-8428(02)00112-9 (Pubitemid 35435286)
12. AW Loren DL Porter EA Stadtmauer DE Tsai 2003 Post-transplant lymphoproliferative disorder: a review Bone Marrow Transplant 31 145 155 12621474 10.1038/sj.bmt.1703806 1:STN:280:DC%2BD3s7gslyhsQ%3D%3D (Pubitemid 36305567)
13. HY Draoua L Tsao DM Mancini LJ Addonizio G Bhagat B Alobeid 2004 T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience Br J Haematol 127 429 432 15521920 10.1111/j.1365-2141.2004.05212.x 1:STN:280:DC%2BD2crltVCitA%3D%3D (Pubitemid 39536595)
14. R Lundell KS Elenitoba-Johnson MS Lim 2004 T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient Am J Surg Pathol 28 967 973 15223970 10.1097/00000478-200407000-00019 (Pubitemid 38856856)
15. F Yang Y Li R Braylan SP Hunger LJ Yang 2008 Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation Pediatr Blood Cancer 50 415 418 17051534 10.1002/pbc.21072
16. V Leblond F Davi F Charlotte R Dorent MO Bitker L Sutton, et al. 1998 Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16 2052 2059 9626203 1:STN:280: DyaK1c3ovFCnsQ%3D%3D
17. G Dotti R Fiocchi T Motta A Gamba E Gotti B Gridelli, et al. 2000 Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant Transplantation 69 827 833 10755535 10.1097/00007890-200003150-00027 1:STN:280:DC%2BD3c3hs1eisw%3D%3D
18. G Opelz B Dohler 2004 Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 222 230 14974943 10.1046/j.1600-6143.2003.00325.x (Pubitemid 38248525)
19. AL Taylor R Marcus JA Bradley 2005 Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation Crit Rev Oncol Hematol 56 155 167 15979320 10.1016/j.critrevonc.2005.03.015 (Pubitemid 41278654)
20. M Ross P Kouretas P Gamberg J Miller M Burge B Reitz, et al. 2006 Ten- and 20-year survivors of pediatric orthotopic heart transplantation J Heart Lung Transplant 25 261 270 16507417 10.1016/j.healun.2005.09.011 (Pubitemid 43290654)
21. SZ Gao SV Chaparro M Perlroth JG Montoya JL Miller S DiMiceli, et al. 2003 Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University J Heart Lung Transplant 22 505 514 12742411 10.1016/S1053-2498(02)01229-9 (Pubitemid 36549048)
22. M Green J Bueno D Rowe G Mazariegos L Qu K Abu-Almagd, et al. 2000 Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children Transplantation 70 593 596 10972215 10.1097/00007890-200008270-00010 1:STN:280:DC%2BD3cvktVyrsw%3D%3D
23. TC Lee B Savoldo CM Rooney HE Heslop AP Gee Y Caldwell, et al. 2005 Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients Am J Transplant 5 2222 2228 16095501 10.1111/j.1600-6143.2005.01002.x (Pubitemid 41648469)
24. S Schubert C Renner M Hammer H Abdul-Khaliq HB Lehmkuhl F Berger, et al. 2008 Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients J Heart Lung Transplant 27 100 105 18187094 10.1016/j.healun.2007.09.027
25. UD Allen G Farkas D Hebert S Weitzman D Stephens M Petric, et al. 2005 Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study Pediatr Transplant 9 450 455 16048596 10.1111/j.1399-3046.2005.00318.x (Pubitemid 41153264)
26. MA Bingler B Feingold SA Miller E Quivers MG Michaels M Green, et al. 2008 Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children Am J Transplant 8 442 445 18211510 1:STN:280:DC%2BD1c%2FlslSnsg%3D%3D
27. R Scheenstra EA Verschuuren A de Haan MJ Slooff TH The CM Bijleveld, et al. 2004 The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients Transpl Infect Dis 6 15 22 15225222 10.1111/j.1399-3062.2004.00044.x 1:STN:280:DC%2BD2czis1SitA%3D%3D (Pubitemid 38954923)
28. DA Axelrod R Holmes SE Thomas JC Magee 2003 Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder Pediatr Transplant 7 223 227 12756048 10.1034/j.1399-3046.2003.00080.x (Pubitemid 36682147)
29. LJ Swinnen MR Costanzo-Nordin SG Fisher EJ O'Sullivan MR Johnson AL Heroux, et al. 1990 Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients N Engl J Med 323 1723 1728 2100991 1:STN:280:DyaK3M%2FmtFyhtg%3D%3D
30. C Quintini T Kato JJ Gaynor T Ueno G Selvaggi P Gordon, et al. 2006 Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center Transplant Proc 38 1755 1758 16908272 10.1016/j.transproceed.2006.05.039 1:STN:280:DC%2BD28vosFejtw%3D%3D (Pubitemid 44190042)
31. KL Cox LS Lawrence-Miyasaki R Garcia-Kennedy ET Lennette OM Martinez SM Krams, et al. 1995 An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation Transplantation 59 524 529 7533344 1:STN:280: DyaK2M7osVehtw%3D%3D
32. S Cao KL Cox W Berquist M Hayashi W Concepcion GB Hammes, et al. 1999 Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus Pediatr Transplant 3 22 26 10359027 10.1034/j.1399-3046.1999. 00002.x 1:STN:280:DyaK1M3osFGhsA%3D%3D (Pubitemid 29234288)
33. BS Younes SV McDiarmid MG Martin JH Vargas JA Goss RW Busuttil, et al. 2000 The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients Transplantation 70 94 99 10919581 1:CAS:528:DC%2BD3cXlvVOlsrw%3D
34. VR Dharnidharka PL Ho DM Stablein WE Harmon AH Tejani 2002 Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study Pediatr Transplant 6 396 399 12390426 10.1034/j.1399-3046.2002.00021.x 1:CAS:528: DC%2BD3sXislWgtr4%3D (Pubitemid 35265190)
35. S Caillard V Dharnidharka L Agodoa E Bohen K Abbott 2005 Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression Transplantation 80 1233 1243 16314791 10.1097/01.tp.0000179639.98338.39 1:CAS:528:DC%2BD2MXht1Gru7nP (Pubitemid 41746802)
36. BD Kahan YK Yakupoglu L Schoenberg RJ Knight SM Katz D Lai, et al. 2005 Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients Transplantation 80 749 758 16210961 10.1097/01.TP. 0000173770.42403.F7 1:CAS:528:DC%2BD2MXhtVynsbvL (Pubitemid 41443756)
37. M Majewski M Korecka P Kossev S Li J Goldman J Moore, et al. 2000 The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders Proc Natl Acad Sci USA 97 4285 4290 10759564 10.1073/pnas.080068597 1:CAS:528:DC%2BD3cXislSnsro%3D (Pubitemid 30226125)
38. M Majewski M Korecka J Joergensen L Fields P Kossev W Schuler, et al. 2003 Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses Transplantation 75 1710 1717 12777861 10.1097/01.TP.0000063934.89714.19 1:CAS:528:DC%2BD3sXms1Grt7w%3D (Pubitemid 36629155)
39. DA Falco RR Nepomuceno SM Krams PP Lee MM Davis O Salvatierra, et al. 2002 Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients Transplantation 74 501 510 12352909 10.1097/00007890-200208270-00012 1:CAS:528:DC%2BD38Xntl2jt7g%3D
40. K Kuzushima N Hayashi A Kudoh Y Akatsuka K Tsujimura Y Morishima, et al. 2003 Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells Blood 101 1460 1468 12393434 10.1182/blood-2002-04-1240 1:CAS:528:DC%2BD3sXht1agu78%3D (Pubitemid 36182521)
41. NE Annels JS Kalpoe RG Bredius EC Claas AC Kroes AD Hislop, et al. 2006 Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution Clin Infect Dis 42 1743 1748 16705581 10.1086/503838 1:CAS:528:DC%2BD28XmsVCgsb0%3D (Pubitemid 43839440)
42. NA Bakker GW van Imhoff EA Verschuuren WJ van Son JJ van der Heide SP Lems, et al. 2005 HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical Transplantation 80 595 599 16177631 10.1097/01.tp.0000173793.03228.bd 1:CAS:528:DC%2BD2MXhtVajs7nL (Pubitemid 41377744)
43. M Subklewe R Marquis S Choquet V Leblond JL Garnier R Hetzer, et al. 2006 Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation Transplantation 82 1093 1100 17060859 10.1097/01.tp.0000235889.05171.12 1:CAS:528: DC%2BD28XhtFSkur7O (Pubitemid 44632126)
44. NA Bakker GW van Imhoff EA Verschuuren WJ van Son 2007 Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation Transpl Int 20 207 218 17291214 10.1111/j.1432-2277.2006. 00416.x 1:CAS:528:DC%2BD2sXjsVyjt7c%3D (Pubitemid 46246535)
45. Swerdlow SH, Webber SA, Chadburn A, Ferry JA, editors. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008.
46. MA Lones S Mishalani IP Shintaku LM Weiss WS Nichols JW Said 1995 Changes in tonsils and adenoids in children with posttransplant lymphoproliferative disorder: report of three cases with early involvement of Waldeyer's ring Hum Pathol 26 525 530 7750936 10.1016/0046-8177(95)90248-1 1:STN:280: DyaK2M3ntVajsw%3D%3D
47. M Benkerrou A Durandy A Fischer 1993 Therapy for transplant-related lymphoproliferative diseases Hematol Oncol Clin North Am 7 467 475 8385662 1:STN:280:DyaK3s3isVCgsA%3D%3D
48. TV Cacciarelli M Green R Jaffe GV Mazariegos A Jain JJ Fung, et al. 1998 Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy Transplantation 66 1047 1052 9808490 10.1097/00007890-199810270-00014 1:CAS:528:DyaK1cXnsFeluro%3D (Pubitemid 28513385)
49. KA Newell EM Alonso PF Whitington DS Bruce JM Millis JB Piper, et al. 1996 Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression Transplantation 62 370 375 8779685 10.1097/00007890-199608150- 00012 1:STN:280:DyaK28zntlertQ%3D%3D
50. VR Dharnidharka VK Douglas SP Hunger RS Fennell 2004 Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient Pediatr Transplant 8 87 90 15009846 10.1046/j.1397-3142.2003.00113.x (Pubitemid 38139792)
51. G Gheorghe EA Albano CC Porter L McGavran Q Wei L Meltesen, et al. 2007 Posttransplant Hodgkin lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature J Pediatr Hematol Oncol 29 112 116 17279008 10.1097/MPH. 0b013e318030c9ea (Pubitemid 46213858)
52. VR Dharnidharka V Douglas-Nikitin 2004 Hodgkin's-like PTLD versus true Hodgkin's disease Pediatr Transplant 8 581 582 15598328 10.1111/j.1399-3046. 2004.00225.x (Pubitemid 40052357)
53. N Sculerati M Arriaga 1990 Otolaryngologic management of posttransplant lymphoproliferative disease in children Ann Otol Rhinol Laryngol 99 445 450 2350129 1:STN:280:DyaK3c3nsVeitQ%3D%3D
54. SD Zangwill DT Hsu MR Kichuk JH Garvin CJ Stolar J Haddad Jr, et al. 1998 Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients J Heart Lung Transplant 17 1161 1166 9883755 1:STN:280:DyaK1M%2FpvVahtg%3D%3D
55. CC Tai JL Curtis JR Szmuszkovicz MV Horn HR Ford MS Woo, et al. 2008 Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality J Pediatr Surg 43 2174 2177 19040929 10.1016/j.jpedsurg.2008.08.044
56. TG Gross JC Bucuvalas JR Park TC Greiner SH Hinrich SS Kaufman, et al. 2005 Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation J Clin Oncol 23 6481 6488 16170157 10.1200/JCO.2005.08.074 1:CAS:528: DC%2BD2MXhtFWqsLjE (Pubitemid 46190239)
57. Addonizio LJ, Boyle GJ, editors. Posttransplant malignancy: risk, factors, incidence, diagnosis, treatment. In: Canter CE, Kirklin JK, editors. Pediatric heart transplantation, vol. 2. Philadelphia: Elsevier; 2007.
58. K Kawa A Sawada M Koyama M Inoue 2007 Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection? Int J Hematol 85 267 269 17483066 10.1532/IJH97.07014 (Pubitemid 46686589)
59. L Quintanilla-Martinez S Kumar F Fend E Reyes J Teruya-Feldstein DW Kingma, et al. 2000 Fulminant EBV(+) T-cell lymphoproliferative disorder following acute/chronic EBV infection: a distinct clinicopathologic syndrome Blood 96 443 451 10887104 1:CAS:528:DC%2BD3cXltVGhtLk%3D
60. A Karras E Thervet C Legendre 2004 Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature Transplantation 77 238 243 14742988 10.1097/01.TP.0000107285.86939.37 (Pubitemid 38155753)
61. N Awaya A Adachi T Mori H Kamata J Nakahara K Yokoyama, et al. 2006 Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma Leuk Res 30 1059 1062 16330097 10.1016/j.leukres.2005.10.022 1:CAS:528:DC%2BD28Xls1artbc%3D (Pubitemid 43831176)
62. H Chisuwa Y Hashikura Y Nakazawa T Kamijo K Nakazawa J Nakayama, et al. 2001 Fatal hemophagocytic syndrome after living-related liver transplantation: a report of two cases Transplantation 72 1843 1846 11740400 10.1097/00007890- 200112150-00024 1:STN:280:DC%2BD3Mnptl2ksQ%3D%3D
63. M Green MG Michaels SA Webber D Rowe J Reyes 1999 The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients Pediatr Transplant 3 271 281 10562971 10.1034/j.1399-3046.1999.00066.x 1:STN:280:DC%2BD3c%2FivVOisw%3D%3D (Pubitemid 29503271)
64. PS Randhawa R Jaffe AJ Demetris M Nalesnik TE Starzl YY Chen, et al. 1992 Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease N Engl J Med 327 1710 1714 1331789 1:STN:280:DyaK3s%2FmtlWisg%3D%3D
65. HJ Delecluse E Kremmer JP Rouault C Cour G Bornkamm F Berger 1995 The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders Am J Pathol 146 1113 1120 7747805 1:STN:280:DyaK2M3ms1Kmtw%3D%3D
66. DM Walling LA Andritsos W Etienne DA Payne JF Aronson CM Flaitz, et al. 2004 Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative disease J Med Virol 74 94 101 15258974 10.1002/jmv.20151 1:CAS:528:DC%2BD2cXntFGltLc%3D (Pubitemid 38988865)
67. WA Mourad A Tulabah A Al Sayed M Raja Y Khafaga H El Gamal, et al. 2006 The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management Arch Pathol Lab Med 130 1649 1653 17076526
68. Y Dror M Greenberg G Taylor R Superina D Hébert L West, et al. 1999 Lymphoproliferative disorders after organ transplantation in children Transplantation 67 990 998 10221483 10.1097/00007890-199904150-00010 1:STN:280:DyaK1M3js1KksA%3D%3D (Pubitemid 29200849)
69. SB Murphy 1980 Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults Semin Oncol 7 332 339 7414342 1:STN:280:DyaL3M%2FhsFGgsA%3D%3D
70. C von Falck B Maecker E Schirg AR Boerner WH Knapp C Klein, et al. 2007 Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring Eur J Radiol 63 427 435 10.1016/j.ejrad.2007.01.007 (Pubitemid 47321032)
71. E Bianchi M Pascual M Nicod AB Delaloye MA Duchosal 2008 Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease Transplantation 85 707 712 18337664 10.1097/TP.0b013e3181661676
72. SM Meehan P Domer M Josephson M Donoghue A Sadhu LT Ho, et al. 2001 The clinical and pathologic implications of plasmacytic infiltrates in percutaneous renal allograft biopsies Hum Pathol 32 205 215 11230708 10.1053/hupa.2001.21574 1:STN:280:DC%2BD3M7pvVegsw%3D%3D (Pubitemid 32193719)
73. MD Pescovitz 2004 The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation Pediatr Transplant 8 9 21 15009836 10.1046/j.1397-3142.2003.00135.x 1:CAS:528:DC%2BD2cXhs1GrtLc%3D (Pubitemid 38139782)
74. V Ganne N Siddiqi B Kamaplath CC Chang EP Cohen BA Bresnahan, et al. 2003 Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder Clin Transplant 17 417 422 14703923 10.1034/j.1399-0012.2003.00054.x (Pubitemid 37236113)
75. S Choquet V Leblond R Herbrecht G Socie AM Stoppa P Vandenberghe, et al. 2006 Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study Blood 107 3053 3057 16254143 10.1182/blood-2005-01-0377 1:CAS:528:DC%2BD28Xjs1Olurs%3D
76. AH Blaes BA Peterson N Bartlett DL Dunn VA Morrison 2005 Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial Cancer 104 1661 1667 16149091 10.1002/cncr.21391 1:CAS:528:DC%2BD2MXhtF2nt7rO (Pubitemid 41437429)
77. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah, et al. 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 11807147 10.1056/NEJMoa011795 1:CAS:528:DC%2BD38XmslGgsw%3D%3D (Pubitemid 34438862)
78. N Mounier J Briere C Gisselbrecht JF Emile P Lederlin C Sebban, et al. 2003 Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 4279 4284 12576316 10.1182/blood-2002-11-3442 1:CAS:528: DC%2BD3sXktFKht7k%3D (Pubitemid 36857789)
79. RU Trappe S Choquet P Reinke M Dreyling HG Mergenthaler U Jager, et al. 2007 Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab Transplantation 84 1708 1712 18165786 10.1097/01.tp.0000295987.12996.19 1:CAS:528:DC%2BD1cXmvVak
80. K Fu DD Weisenburger WW Choi KD Perry LM Smith X Shi, et al. 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma J Clin Oncol 26 4587 4594 18662967 10.1200/JCO.2007.15.9277 1:CAS:528:DC%2BD1cXht1KqtLfI
81. M Orjuela TG Gross YK Cheung B Alobeid E Morris MS Cairo 2003 A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation Clin Cancer Res 9 3945S 3952S 14506193 1:CAS:528: DC%2BD3sXosVOksbs%3D
82. RL Elstrom C Andreadis NA Aqui VN Ahya RD Bloom SC Brozena, et al. 2006 Treatment of PTLD with rituximab or chemotherapy Am J Transplant 6 569 576 16468968 10.1111/j.1600-6143.2005.01211.x 1:CAS:528:DC%2BD28Xit12gt7k%3D (Pubitemid 43382145)
83. SM Aalto E Juvonen J Tarkkanen L Volin T Ruutu PS Mattila, et al. 2003 Lymphoproliferative disease after allogeneic stem cell transplantation-pre- emptive diagnosis by quantification of Epstein-Barr virus DNA in serum J Clin Virol 28 275 283 14522066 10.1016/S1386-6532(03)00022-2 (Pubitemid 37159368)
84. DP Funch AM Walker G Schneider NJ Ziyadeh MD Pescovitz 2005 Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients Am J Transplant 5 2894 2900 16303002 10.1111/j.1600-6143.2005.01115.x 1:STN:280:DC%2BD2MnitFKmtg%3D%3D (Pubitemid 43923949)
85. L Hierro R Diez-Dorado C Diaz A De la Vega E Frauca C Camarena, et al. 2008 Efficacy and safety of valganciclovir in liver-transplanted children infected with Epstein-Barr virus Liver Transpl 14 1185 1193 18668670 10.1002/lt.21498
86. M Green J Reyes S Webber D Rowe 2001 The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation Transpl Infect Dis 3 97 103 11395975 10.1034/j.1399-3062.2001. 003002097.x 1:STN:280:DC%2BD3MzivV2kuw%3D%3D (Pubitemid 32452924)
87. CV Paya JJ Fung MA Nalesnik E Kieff M Green G Gores, et al. 1999 Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting Transplantation 68 1517 1525 10589949 10.1097/00007890-199911270-00015 1:STN:280:DC%2BD3c%2FlsFyqtg%3D%3D
88. CL Davis 1998 The antiviral prophylaxis of post-transplant lymphoproliferative disorder Springer Semin Immunopathol 20 437 453 9870256 10.1007/BF00838054 1:CAS:528:DyaK1cXnsFGhu7c%3D
89. M Green MG Michaels BZ Katz M Burroughs D Gerber BL Shneider, et al. 2006 CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients Am J Transplant 6 1906 1912 16889546 10.1111/j.1600-6143.2006.01394.x 1:CAS:528:DC%2BD28XoslCntbg%3D (Pubitemid 44024963)
90. A Humar D Hebert HD Davies A Humar D Stephens B O'Doherty, et al. 2006 A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder Transplantation 81 856 861 16570008 10.1097/01.tp.0000202724.07714.a2 1:CAS:528:DC%2BD28XivFShsLc%3D
91. SA Birkeland HK Andersen SJ Hamilton-Dutoit 1999 Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol Transplantation 67 1209 1214 10342310 10.1097/00007890-199905150-00002 1:CAS:528:DyaK1MXjsleku78%3D (Pubitemid 29239469)
92. RR Nepomuceno CE Balatoni Y Natkunam AL Snow SM Krams OM Martinez 2003 Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas Cancer Res 63 4472 4480 12907620 1:CAS:528:DC%2BD3sXmtFersrg%3D
93. M El-Salem PN Raghunath M Marzec P Wlodarski D Tsai E Hsi, et al. 2007 Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders Lab Invest 87 29 39 17075574 10.1038/labinvest. 3700494 1:CAS:528:DC%2BD28XhtlaktrjL (Pubitemid 44973651)
94. J Pascual 2007 Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors Nephrol Dial Transplant 22 Suppl 1 i27 i35 17456616 10.1093/ndt/gfm088 1:CAS:528:DC%2BD2sXntVCgurY%3D (Pubitemid 47073742)
95. JA Sanchez-Brotons JM Sobrino-Marquez E Lage-Galle N Romero-Rodriguez A Guisado J Jimenez-Diaz, et al. 2008 Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy Transplant Proc 40 3046 3048 19010188 10.1016/j.transproceed.2008.08.111 1:CAS:528:DC%2BD1cXhtlyksr3N
96. AO Zuckermann AZ Aliabadi 2009 Calcineurin-inhibitor minimization protocols in heart transplantation Transpl Int 22 78 89 18954366 10.1111/j.1432-2277.2008.00771.x 1:CAS:528:DC%2BD1MXhsFGkt7Y%3D
97. C Jimenez-Rivera Y Avitzur AH Fecteau N Jones D Grant VL Ng 2004 Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma Pediatr Transplant 8 243 248 15176961 10.1111/j.1399-3046.2004.00156.x 1:CAS:528:DC%2BD2cXlslGltbo%3D (Pubitemid 38788551)
98. S Kusuki Y Hashii N Fukushima S Takizawa S Tokimasa S Kogaki, et al. 2009 Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation Int J Hematol 89 209 213 19156500 10.1007/s12185-008-0250-9
99. KM Posfay-Barbe CA Siegrist 2009 Immunization and transplantation-what is new and what is coming? Pediatr Transplant 13 404 410 19032408 1:CAS:528:DC%2BD1MXmvFyisrg%3D